Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 5/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1702029 | 0.89 | MAPT (0.45) | KDM4EALDH1A1MAPTPDE4AADORA2A | |
| SCHEMBL4960409 | 0.84 | POLB (0.46) | KDM4EALDH1A1SMN1; SMN2MAPTPDE4A | |
| SCHEMBL18072360 | 0.83 | HSD17B10 (0.53) | KDM4EALDH1A1MAPTHSD17B10KMT2A | |
| SCHEMBL7835947 | 0.80 | ALDH1A1 (0.38) | KDM4EALDH1A1SMN1; SMN2MAPTPDE4A | |
| SCHEMBL1946240 | 0.79 | KMT2A (0.61) | KDM4EALDH1A1SMN1; SMN2GLAMAPT | |
| SCHEMBL5742355 | 0.79 | MAPT (0.41) | KDM4EALDH1A1SMN1; SMN2GLAMAPT | |
| SCHEMBL8768819 | 0.78 | TYMP (0.44) | KDM4EALDH1A1SMN1; SMN2MAPTHPGD | |
| SCHEMBL27385314 | 0.77 | ATM (0.43) | KDM4EALDH1A1SMN1; SMN2MAPTHPGD | |
| SCHEMBL29776965 | 0.76 | B3GNT2 (0.43) | KDM4EALDH1A1SMN1; SMN2MAPTPDE4A | |
| SCHEMBL6027678 | 0.74 | TYMP (0.46) | KDM4EALDH1A1KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018213777-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-11-22 | — | — | WO | disclosed |
| US-8349848-B2 | Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors | Dogwoof Pharmaceuticals, Inc. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349848-B2 | Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors | Dogwoof Pharmaceuticals, Inc. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349848-B2 | Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors | Dogwoof Pharmaceuticals, Inc. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2009-03-26 | — | — | US | disclosed |
| US-7470697-B2 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470697-B2 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470697-B2 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080125425-A1 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2008-05-29 | — | — | US | disclosed |
| US-20080125425-A1 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2008-05-29 | — | — | US | disclosed |
| US-20080125425-A1 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2008-05-29 | — | — | US | disclosed |
| WO-2008027585-A2 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-06 | — | — | WO | disclosed |
| US-20060252780-A1 | Fused pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1637532-A1 | FUSED PYRIMIDINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125425-A1 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors | ADORA2B, ADORA2A, ADORA3 | KDM4E 2977/4885USP2 4367/4885ALDH1A1 1050/4885 |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADORA2B, ADORA2A, ADORA3 | KDM4E 3826/4885USP2 4308/4885ALDH1A1 1180/4885 |
| US-20060252780-A1 | Fused pyrimidine derivatives | INSR, GPR119, NPY4R | KDM4E 1514/4885USP2 4712/4885ALDH1A1 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.